Cholecystectomy: A way forward and back to metabolic syndrome?

Gabriella Garruti; David Q.H. Wang; Agostino Di Ciaula; Piero Portincasa

doi:10.1038/labinvest.2017.129

Cholecystectomy: A way forward and back to metabolic syndrome?

Gabriella Garruti, David Q.H. Wang, Agostino Di Ciaula, Piero Portincasa

Research output: Contribution to journal › Review article › peer-review

19 Scopus citations

Abstract

The gallbladder provides rhythmic secretion of concentrated bile acids (BAs) during fasting and postprandially contributes to digestion of dietary lipids. In addition, BAs activate metabolic pathways governing gluco-lipid homeostasis and energy expenditure via the farnesoid X nuclear receptor (FXR), G protein-coupled BA receptor 1 (GPBAR-1), and fibroblast growth factor 19 (FGF19) in the liver, intestine, brown fat, and muscle. Cholecystectomy is standard treatment worldwide for symptomatic gallstone patients. As excellently reviewed by Chen et al, cholecystectomy may disrupt enterohepatic recycling of, and signaling by, BAs. Further studies are needed to investigate whether gallbladder removal is an independent risk factor for development of the metabolic syndrome.

Original language	English (US)
Pages (from-to)	4-6
Number of pages	3
Journal	Laboratory Investigation
Volume	98
Issue number	1
DOIs	https://doi.org/10.1038/labinvest.2017.129
State	Published - Jan 1 2018
Externally published	Yes

ASJC Scopus subject areas

Pathology and Forensic Medicine
Molecular Biology
Cell Biology

Access to Document

10.1038/labinvest.2017.129

Cite this

@article{ef47cff5d8f540be9813f7e95141144b,

title = "Cholecystectomy: A way forward and back to metabolic syndrome?",

abstract = "The gallbladder provides rhythmic secretion of concentrated bile acids (BAs) during fasting and postprandially contributes to digestion of dietary lipids. In addition, BAs activate metabolic pathways governing gluco-lipid homeostasis and energy expenditure via the farnesoid X nuclear receptor (FXR), G protein-coupled BA receptor 1 (GPBAR-1), and fibroblast growth factor 19 (FGF19) in the liver, intestine, brown fat, and muscle. Cholecystectomy is standard treatment worldwide for symptomatic gallstone patients. As excellently reviewed by Chen et al, cholecystectomy may disrupt enterohepatic recycling of, and signaling by, BAs. Further studies are needed to investigate whether gallbladder removal is an independent risk factor for development of the metabolic syndrome.",

author = "Gabriella Garruti and Wang, {David Q.H.} and {Di Ciaula}, Agostino and Piero Portincasa",

year = "2018",

month = jan,

day = "1",

doi = "10.1038/labinvest.2017.129",

language = "English (US)",

volume = "98",

pages = "4--6",

journal = "Laboratory Investigation",

issn = "0023-6837",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Cholecystectomy

T2 - A way forward and back to metabolic syndrome?

AU - Garruti, Gabriella

AU - Wang, David Q.H.

AU - Di Ciaula, Agostino

AU - Portincasa, Piero

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The gallbladder provides rhythmic secretion of concentrated bile acids (BAs) during fasting and postprandially contributes to digestion of dietary lipids. In addition, BAs activate metabolic pathways governing gluco-lipid homeostasis and energy expenditure via the farnesoid X nuclear receptor (FXR), G protein-coupled BA receptor 1 (GPBAR-1), and fibroblast growth factor 19 (FGF19) in the liver, intestine, brown fat, and muscle. Cholecystectomy is standard treatment worldwide for symptomatic gallstone patients. As excellently reviewed by Chen et al, cholecystectomy may disrupt enterohepatic recycling of, and signaling by, BAs. Further studies are needed to investigate whether gallbladder removal is an independent risk factor for development of the metabolic syndrome.

AB - The gallbladder provides rhythmic secretion of concentrated bile acids (BAs) during fasting and postprandially contributes to digestion of dietary lipids. In addition, BAs activate metabolic pathways governing gluco-lipid homeostasis and energy expenditure via the farnesoid X nuclear receptor (FXR), G protein-coupled BA receptor 1 (GPBAR-1), and fibroblast growth factor 19 (FGF19) in the liver, intestine, brown fat, and muscle. Cholecystectomy is standard treatment worldwide for symptomatic gallstone patients. As excellently reviewed by Chen et al, cholecystectomy may disrupt enterohepatic recycling of, and signaling by, BAs. Further studies are needed to investigate whether gallbladder removal is an independent risk factor for development of the metabolic syndrome.

UR - http://www.scopus.com/inward/record.url?scp=85042747466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042747466&partnerID=8YFLogxK

U2 - 10.1038/labinvest.2017.129

DO - 10.1038/labinvest.2017.129

M3 - Review article

C2 - 29297503

AN - SCOPUS:85042747466

SN - 0023-6837

VL - 98

SP - 4

EP - 6

JO - Laboratory Investigation

JF - Laboratory Investigation

IS - 1

ER -

Cholecystectomy: A way forward and back to metabolic syndrome?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this